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Introduction: There is no information on the uptake of Intensive Insulin Therapy (IIT) before the Normoglycemia in
Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation (NICE-SUGAR) trial in Australia and
New Zealand (ANZ) and on the bi-national response to the trial, yet such data would provide important
information on the evolution of ANZ practice in this field. We aimed to study ANZ glycaemic control before and
after the publication of the results of the NICE-SUGAR trial.
Methods: We analysed glucose control in critically ill patients across Australia and New Zealand during a two-year
period before and after the publication of the NICE-SUGAR study. We used the mean first day glucose (Glu1) (a
validated surrogate of ICU glucose control) to define practice. The implementation of an IIT protocol was presumed
if the median of Glu1 measurements was <6.44 mmol/L for a given ICU. Hypoglycaemia was categorised as severe
(glucose ≤2.2 mmol/L) or moderate (glucose ≤3.9 mmol/L).
Results: We studied 49 ICUs and 176,505 patients. No ICU practiced IIT before or after NICE-SUGAR. Overall, Glu1
increased from 7.96 (2.95) mmol/L to 8.03 (2.92) mmol/L (P <0.0001) after NICE-SUGAR. Similar increases were noted
in all patient subgroups studied (surgical, medical, insulin dependent diabetes mellitus, ICU stay >48/<48 hours).
The rate of severe and moderate hypoglycaemia before and after NICE-SUGAR study were 0.59% vs. 0.55% (P =0.33)
and 6.62% vs. 5.68% (P <0.0001), respectively. Both crude and adjusted mortalities declined over the study period.
Conclusions: IIT had not been adopted in ANZ before the NICE-SUGAR study and glycaemic control corresponded
to that delivered in the control arm of NICE-SUGAR trial. There were only minor changes in practice after the trial
toward looser glycaemic control. The rate of moderate hypoglycaemia and mortality decreased along with such
changes.Introduction
Stress-related hyperglycaemia was traditionally considered
a potentially protective physiological reaction to stress [1].
Increased levels of blood glucose, however, are associated
with increased morbidity and/or mortality [2-5]. This as-
sociation triggered randomised controlled trials of inten-
sive insulin therapy from 2001 to 2009 [6-8]. The first
single centre trial of intensive insulin therapy (IIT) found
a beneficial effect in surgical critically ill patients [6]. The* Correspondence: maija.kaukonen@monash.edu
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reproduction in any medium, provided the orsecond single centre study [7] in medical patients found
benefit only in patients who stayed in ICU for more than
three days. The third (Normoglycemia in Intensive Care
Evaluation and Surviving Using Glucose Algorithm Regu-
lation (NICE-SUGAR)) multicentre study randomized
6,104 patients from Canada, Australia and New Zealand
(ANZ) to intensive or conventional glucose control [8]
and found a significant increase in mortality in patients
with IIT. A recent meta-analysis confirmed lack of
benefit and higher risk of hypoglycaemia with IIT [9].
Hypoglycaemia is strongly associated with increased risk
of mortality as is shown for NICE-SUGAR study pa-
tients [10].
Recommendations on glucose treatment in critically ill
patients have changed in response to new evidence; fromral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[11] to glucose control <8.3 mmol/L in patients with se-
vere sepsis [12,13] to looser control of glucose levels
while awaiting for more evidence [14] and finally to
moderate glucose control (<10 mmol/L) for all critically
ill patients [15,16].
Two important issues, among others, however, remain
to be addressed. The first is the representativeness of
existing evidence on glycaemic control in ANZ ICUs be-
fore NICE-SUGAR. An inception cohort study with 29
ICUs and 939 patients described glucose control prac-
tice and glycaemic control in ANZ before the NICE-
SUGAR study [17]. However, it is unknown to what de-
gree these patients were representative of ANZ practice.
The second is whether changes in available data have
been translated into practice and have affected glycaemic
control in ANZ. The first is important in supporting
the robustness of the findings of the NICE-SUGAR
study; the second in defining how evidence might be
translated into practice at a bi-national level after a piv-
otal trial.
The Australian and New Zealand Intensive Care Society
Adult Patient Database (ANZICS APD) is a high quality
database, which routinely collects lowest and highest
glucose values during the first 24 h in ICU [18]. In a study
involving >8,000 patients and close to 200,000 glucose
measurements, the average glucose levels on Day 1 was
found to be an excellent surrogate of overall ICU glucose
control with a mean difference of only 0.17 mmol/L [19].
Accordingly, we used data from the ANZICS APD to
test the hypotheses that 1.) glycaemic control practice
in ANZ at the time of the NICE-SUGAR trial was
equivalent to that prescribed to the trial control group
and 2.) the NICE-SUGAR trial results have been trans-
lated into practice with the mean glucose level of
8.0 mmol/L.
Materials and methods
We conducted a retrospective analysis of the prospec-
tively collected Australian and New Zealand Intensive
Care Society Adult Patient Database [18]. The ANZICS-
APD is an established voluntary bi-national database run
by the ANZICS Centre for Outcome and Resource
Evaluation (CORE) which contains information on 80%
of the ICU admissions in Australia and New Zealand
[20]. Non-contributing sites are predominantly small
rural and private hospitals. The information collection
includes clinical and physiological information as well as
outcome data for routine quality surveillance [21]. Data
are collected under the Quality Assurance Legislation of
the Commonwealth of Australia (Part VC Health Insur-
ance Act 1973, Commonwealth of Australia). Access to
the data was granted by the ANZICS-CORE ManagementCommittee in accordance with standing protocols. The
study was approved by The Alfred Health Human Ethics
Committee.Glucose control
The highest and the lowest blood glucose measurement
during the first 24 hours after ICU admission are
recorded into APD. These two values were used to de-
fine all glycaemic indices in the study. The mean value
of these measurements (Glu1) has been shown to act as
an accurate surrogate of glucose control for the whole
duration of ICU stay [19]. Accordingly, we used the Glu1
value as a surrogate of glucose control for each patient
during their ICU stay. The first day lowest glucose meas-
urement was used to define the rate of hypoglycaemia.
The rate of hypoglycaemia was calculated by dividing
the number of patients with hypoglycaemia by all pa-
tients eligible for assessment. Severe hypoglycaemia was
defined as glucose value ≤2.2 mmol/L and moderate
hypoglycaemia as a glucose value ≤3.9 mmol/L [6-8].
The glucose control for each ICU was defined by cal-
culating the median value of all patients’ Glu1 values.
The implementation of tight glucose control in clinical
practice for the ICU was presumed if the median of the
Glu1 measurement was <6.44 mmol/L. The value of
6.44 mmol/L was chosen as it represents the upper limit
of 95% confidence interval of the observed time-
averaged mean glucose value in the IIT arm of NICE-
SUGAR [8].
For outcome analysis, the ICUs were divided into
quartiles according to the extent of change in their Glu1
values. The first quartile (Q1) represents ICUs with the
least increase in the Glu1 value and the fourth quartile
(Q4) represents ICUs with the highest increase.Selection of ICUs and time period
All ICUs providing data to APD were potentially eligible
for the study. We ensured the representativeness of the
patient population for a given ICU by excluding ICUs
that had not annually provided at least 80% of the first
day glucose measurements for their patients for the dur-
ation of the entire study period. As the number of ICUs
fulfilling this criterion during early years of millennium
was low, we could not reliably study the translation of
the first two large randomised controlled trials (RCTs)
into practice. Therefore, we restricted the study period
around the latest large RCT (NICE-SUGAR [8]). NICE-
SUGAR was published 6 March 2009 and, accordingly,
we collected patients for two years before NICE-
SUGAR (from 1February 2007 to 31 January 2009) and
two years after (from 1 June 2009 to 31 May 2011). We
also studied time-related changes by splitting the before
Table 1 Median of the mean first day glucose







Rural ICUs 7.15 (6.0 to 8.6) 7.15 (6.0 to 8.9) 0.52
Metropolitan ICUs 7.65 (6.4 to 9.35) 7.55 (6.3 to 9.35) 0.07
Tertiary ICUs 7.55 (6.4 to 8.8) 7.70 (6.55 to 9.05) <0.0001
Private ICUs 7.45 (6.4 to 8.5) 7.40 (6.35 to 8.45) 0.004
NICE-SUGAR ICUs 7.55 (6.35 to 8.9) 7.65 (6.45 to 9.05) <0.0001
No NICE-SUGAR ICUs 7.50 (6.4 to 8.8) 7.55 (6.45 to 8.9) <0.0001
ICU, intensive care unit; IQR, median; NICE-SUGAR, Normoglycemia in Intensive
Care Evaluation and Surviving Using Glucose Algorithm Regulation.
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periods.
Patients
We studied all patients treated in the participating ICUs
during the study period. The results are presented also
in patient subgroups as reported in previous large RCTs
by admission diagnosis: medical [7] or surgical [6] and
insulin-dependent diabetes mellitus (IDDM) reported at
admission [22]. We also analysed patients with an ICU
stay >48 hours [7,8].
Statistical analysis
Data are presented as mean (standard deviation, SD) or
median (interquartile range, IQR). The variables are
compared using Student’s t-test, Wilcoxon Rank Sum
test or Chi-square test depending on the nature and dis-
tribution of the variable to be analysed. Hospital mortal-
ity was adjusted by Acute Physiology and Chronic
Health Evaluation III (APACHE III) risk of death. We
performed logistic regression analyses for both crude
and adjusted hospital mortality with the first six-month
period as the reference. To further account for temporal
changes over time, segmented regression analysis of
interrupted time series was performed on the number of
events occurring each month before and after NICE-
SUGAR, with the mean APACHE III score for all
patients within each monthly period also included as a
covariate to indirectly account for patient severity. Seg-
mented regression analysis was performed by fitting a
line before NICE-SUGAR, a separate line after NICE-
SUGAR, and a binomial term for before/after to deter-
mine if there is significant vertical shift between the two
periods. All data were analysed by SAS Version 9.2 (SAS
Institute Inc., Cary, NC, USA). Two-tailed P-value of 0.01
was considered as statistically significant.
Results
Of 132 ICUs providing data to the APD, 49 fulfilled the
selection criteria and of them, 9 (18%) participated in
NICE-SUGAR. During the study period, 176,505 patients
were admitted to these ICUs. Patient characteristics be-
fore and after NICE-SUGAR study are presented in the
Additional file 1: Table A1.
Glucose control in ICUs
No ICU applied IIT in their clinical practice either be-
fore or after the publication of NICE-SUGAR study.
Overall, 28 of the 49 ICUs had an increase in the median
Glu1 value. Of the nine ICUs that had participated in
NICE-SUGAR, five slightly loosened their glucose con-
trol and four ICUs slightly tightened it after the publica-
tion of results. The ICUs in NICE-SUGAR study had
slightly looser glucose control before the study than theICUs not participating in NICE-SUGAR. Overall, both
ICU types (participating and not participating in NICE-
SUGAR) loosened their glucose control after the publica-
tion of the study results, the increase being slightly higher
in ICUs participating to NICE-SUGAR (Table 1).
Rural ICUs had the tightest glucose control and
metropolitan ICUs the loosest glucose control before
NICE-SUGAR study (Table 1). After the NICE-SUGAR
study, tertiary ICUs loosened their glucose control, rural
or metropolitan ICUs made no changes (Table 1). Surpris-
ingly, private ICUs tightened their glucose control after
NICE-SUGAR study. However, all these changes were mi-
nute in extent and unlikely to be clinically significant.
Glucose control at patient level
The mean (SD) value of Glu1 increased from 7.96 (2.95)
mmol/L to 8.03 (2.92) mmol/L (P <0.0001) after NICE-
SUGAR in all patients (Table 2). Statistically significant
increases were noted in all patient subpopulations studied:
surgical, medical, IDDM, no-IDDM, ICU stay more or less
than 48 hours (Table 2).
Glucose control over time
The means of Glu1 values over consecutive six-month
periods before and after the NICE-SUGAR study in all
patients as well as in patient subgroups (surgical, medical,
IDDM/no-IDDM, ICU stay >48 h/<48 h) are presented in
Figure 1.
Severe and moderate hypoglycaemia
The rates of severe hypoglycaemia were 0.59% and
0.55% (P = 0.33) in all patients before and after NICE-
SUGAR publication, respectively (Table 3). There were
no statistically significant differences in the rates of se-
vere hypoglycaemia before and after NICE-SUGAR pub-
lication in any patient subgroup (Table 3). The rate of
moderate hypoglycaemia decreased by 14.2% in the over-
all patient population as well as in patient subgroups,
Table 2 Mean first day glucose (Glu1, in mmol/L) in






All patients 7.96 (2.95) 8.03 (2.92) <0.0001
Surgical patients 7.8 (2.2) 7.9 (2.2) <0.0001
Medical patients 8.1 (3.6) 8.2 (3.5) 0.002
IDDM patients 10.8 (5.3) 11.2 (5.4) <0.0001
Non-IDDM patients 7.8 (2.7) 7.8 (2.7) <0.0001
Patients with >48 h ICU stay 8.2 (3.0) 8.3 (2.9) <0.0001
Patients with <48 h ICU stay 7.8 (2.9) 7.9 (2.9) <0.0001
All numbers are mean (SD). IDDM, insulin-dependent diabetes mellitus; NICE-
SUGAR, Normoglycemia in Intensive Care Evaluation and Surviving Using
Glucose Algorithm Regulation.
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IDDM (Table 3). Moderate hypoglycaemia rate de-
creased in ICUs not participating into NICE-SUGAR but
not in ICUs conducting the study (Table 3). In rural and
metropolitan ICUs, the rate of moderate hypoglycaemia
remained the same, whereas in tertiary and private ICUs
the rates decreased from before to after NICE-SUGAR
(Table 3).Diabetic patients
The patients with IDDM had the highest Glu1 values
both before and after NICE-SUGAR study as well as and
the highest increase in Glu1 (Figure 1, Table 2). The rate
of severe and moderate hypoglycaemia in patients with
IDDM was more than two-fold that in other patient sub-
groups (Table 3). Patients with IDDM were the only pa-
tient subgroup where crude mortality did not decrease
from before to after NICE-SUGAR (Table 4).Outcomes of patients
ICU length of stay increased after NICE-SUGAR, but
hospital length of stay decreased in all patients (Table 5).
The outcomes of all patients before and after NICE-
SUGAR study are presented in Table 5. Unadjusted mor-
tality declined over time during the whole study period
(Table 5, Figure 1). There was a decrease in unadjusted
mortality in all patient subgroups before vs. after NICE-
SUGAR periods. It was statistically significant in all pa-
tient subgroups except for IDDM patients (Table 4). The
adjusted mortality decreased during the whole study
period (Figure 2).
In quartiles according to the change in mean Glu1, the
unadjusted mortality decreased to some degree in all
quartiles. However, after adjustment for patient severity,
only patients from ICUs with the smallest increase in
Glu1 (Q1) displayed a statistically significant decline in
mortality (Figure 3).In the segmented time series analysis of hospital mor-
tality, there was no change between before and after
NICE-SUGAR periods (Figure 4, P = 0.29).
Discussion
Key findings
We studied clinical practice before and after a key
multicentre randomised controlled study of glucose con-
trol in >170,000 patients from 49 ICUs in ANZ. Our
findings confirm previously published survey data that
IIT was not practiced in ANZ prior to NICE-SUGAR.
Glycaemic control in all patients before NICE-SUGAR
corresponded to the control group of the trial. We found
that only minute changes in glycaemic control toward
looser control followed the publication of the study. The
change in glycaemic control applied similarly to all pa-
tient subgroups except for IDDM patients. The rate of
severe hypoglycaemia remained unchanged, whereas the
rate of moderate hypoglycaemia decreased by 14% after
NICE-SUGAR. IDDM patients had highest Glu1−values,
highest increase in Glu1 values, and highest rates of
moderate and severe hypoglycaemia before and after
NICE-SUGAR. The adjusted mortality decreased over
the whole study period.
Relationship to previous studies
The mean Glu1 for all patients in our study before
NICE-SUGAR was 7.96 mmol/L. This is in accordance
with the time-averaged mean glucose value of 8.0 mmol/L
in the control group of NICE-SUGAR [8]. In each sub-
group, glycaemic control approximated to 8 mmol/L,
except for patients with IDDM. As the number of
IDDM patients represented only 3% of all patients be-
fore NICE-SUGAR, their impact on overall glycaemic
control was small.
The quality requirement for data supply for individual
ICUs was stringent. As the possible bias caused by miss-
ing data is of minor concern, it is reasonable to argue
that the results of glycaemia in ICUs reflect the true
practice of ANZ ICUs at that time. According to our re-
sults, IIT was not standard practice in ANZ as none of
the ICUs had their median Glu1 below the upper limit
of the 95% confidence interval of glycaemia reported in
the IIT arm of NICE-SUGAR [8]. In an observational
study conducted in ANZ ICUs and published in 2003,
41% of ICUs reported having implemented tight glucose
control in their clinical practice for at least some patient
subgroups [17]. Simultaneous observational data, however,
displayed a mean first day glucose value of 8.7 mmol/L
[23] suggesting that most ICUs in ANZ did not, in fact,
practice IIT.
A nationwide translational study in Germany showed
that 65% of ICUs perceived having tight glucose control
in practice for patients with sepsis, but only 6% of patients
Figure 1 Glu1, mortality and Glu1 in subgroups over time before and after NICE-SUGAR. Mean first day glucose (SE, Glu1, blue circles) in all
patients with crude hospital mortality (SE, black squares) in four consecutive six-month periods before (periods 1 to 4) and after (periods 5 to 8)
Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation (NICE-SUGAR) study (upper panel). Mean Glu1
values in patient subgroups (surgical/medical, IDDM/no IDDM, ICU stay >48 h/ICU stay <48 h) in the same six-month periods (lower panel).
IDDM, insulin-dependent diabetes mellitus.
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There are no previous reports of national level transla-
tion of glycaemic control recommendations into prac-
tice in critically ill patients. Previous studies have shown
that the translation of study knowledge of simple, cheap
and well-recognized therapies may be poor [25-27].
The loosened glycaemic control after NICE-SUGAR
was reflected by the rates of moderate hypoglycaemia.
The rates of moderate hypoglycaemia were roughly one-
third lower than the 15.8% seen in the control arm of
NICE-SUGAR [10]. A partial explanation for this dif-
ference may be that we had only first day glucose mea-
surements available. The median time of occurrence of
moderate hypoglycaemia in NICE-SUGAR was one day,indicating that half of moderate hypoglycaemia occurred
after the first day [10]. There is no validation yet that the
incidence of hypoglycaemia on Day 1 is a robust surrogate
for the overall incidence of hypoglycaemia.
The rate of severe hypoglycaemia remained unchanged
in the overall patient population as well as in the subgroups
despite looser glycaemic control after NICE-SUGAR. The
rates of severe hypoglycaemia in the control arms of the
three RCTs were 0.8% [6], 3.1% [7] and 0.5% [8]. The
rate in our unselected patient population approximated
that of the first Leuven and NICE-SUGAR studies. In
medical patients, our clinical data showed much lower
incidence of severe hypoglycaemia than the rate in the
second Leuven study which included medical patients
Table 3 Rate of moderate and severe hypoglycaemia during the first 24 hours after ICU admission
Severe hypoglycaemia Moderate hypoglycaemia
Glucose ≤2.2 mmol/L Glucose ≤3.9 mmol/L
Before NICE-SUGAR After NICE-SUGAR P Before NICE-SUGAR After NICE-SUGAR P
All patients 0.59% (449/76,600) 0.55% (489/88,896) 0.33 6.62% (5,076/76,600) 5.68% (5,051/88,896) <0.0001
Surgical patients 0.26% (106/40,847) 0.23% (109/47,670) 0.35 4.48% (1,828/40,847) 3.17% (1,511/47,670) <0.0001
Medical patients 0.96% (339/35,433) 0.93% (380/41,077) 0.65 9.12% (3,230/35,433) 8.61% (3,531/41,077) 0.012
IDDM patients 1.72% (43/2,499) 1.55% (38/2,454) 0.63 14.21% (355/2,499) 13.20% (324/2,454) 0.3
No-IDDM patients 0.57% (286/49,995) 0.52% (310/59,966) 0.22 6.79% (3,394/49,995) 5.64% (3,385/59,966) <0.0001
Patients with >48 h ICU stay 0.63% (201/32,089) 0.64% (241/37,702) 0.83 7.85% (2,520/32,089) 6.87% (2,591/37,702) <0.0001
Patients with <48 h ICU stay 0.56% (248/44,488) 0.48% (248/51,169) 0.12 5.74% (2,554/44,488) 4.80% (2,458/51,169) <0.0001
NICE-SUGAR ICU 0.60% (100/16,794) 0.57% (111/19,346) 0.79 5.69% (955/16,794) 5.62% (1,087/19,346) 0.78
Not NICE-SUGAR ICU 0.58% (349/59,806) 0.54% (378/69,550) 0.34 6.89% (4,121/59,806) 5.70% (3,964/69,550) <0.0001
Hospital level
Rural 0.66% (31/4,708) 0.6% (27/4,506) 0.72 6.65% (313/4,708) 6.88% (310/4,506) 0.66
Metropolitan 0.73% (83/11,414) 0.79% (104/13,128) 0.56 6.59% (752/11,414) 6.51% (854/13,128) 0.79
Tertiary 0.66% (301/45,756) 0.61% (319/52,634) 0.31 7.65% (3,500/45,756) 6.5% (3,421/52,364) <0.0001
Private 0.23% (34/14,722) 0.21% (39/18,628) 0.68 3.47% (511/14,722) 2.5% (466/18,628) <0.0001
The data are given as percentages (number of patients with the event/number of patients with data available). ICU, Intensive Care Unit; IDDM, Insulin dependent
diabetes mellitus; NICE-SUGAR, Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation.
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after ICU admission.
The patients with IDDM had higher Glu1 than pa-
tients in any other subgroup, both before and after
NICE-SUGAR. In the second Leuven or NICE-SUGAR
studies, the mortality in diabetic patients was not dif-
ferent between the treatment groups [7,8]. In a large ob-
servational study, hyperglycaemia was associated with
increased mortality in non-diabetic patients whereas in
diabetic patients the risk was much lower, suggesting
that patients with IDDM may have a different biological
response to hyperglycaemia [22] or that in patients with
DM hyperglycaemia is indicative of a lesser degree of
stress of illness severity. Interestingly, the Glu1 values in







n = 82,740 n = 93,765
Medical patients* 19.8% (7,569) 18.5% (8,020) <0.0001
Surgical patients* 5.4% (2,345) 4.91% (2,427) 0.0008
IDDM patients* 13.9% (360) 11.86% (297) 0.029
No-IDDM patients* 12.07% (6,566) 10.93% (6,943) <0.0001
Patients with >48 h
ICU stay*
16.58% (5,489) 15.32% (5,897) <0.0001
Patients with <48 h
ICU stay*
9.06% (4,496) 8.32% (4,596) <0.0001
*percentage (number of events). NICE-SUGAR, Normoglycemia in Intensive
Care Evaluation and Surviving Using Glucose Algorithm Regulation.above observational study suggesting that there might be
greater difficulty in controlling glycaemia in diabetic pa-
tients or that tight glycaemic control is less vigorously
pursued or both [22].
IDDM patients had the highest Glu1 of all patient sub-
groups along with the highest rate of both severe and
moderate hypoglycaemia, reflecting the highest variabil-
ity in glucose values of all patient subgroups. Although
hyperglycaemia does not seem to be as harmful in dia-
betics as in non-diabetic patients [22], higher variability
of blood glucose values has been associated with in-
creased risk of mortality in overall critically ill patients
[28]. Interestingly, we could not demonstrate a decrease
in mortality in IDDM patients. Finally, overall mortality
decreased during the study period, even when adjusted






n = 82,740 n = 93,765
ICU LOS
(hours, IQR)
39.7 (21.1 to 80.1) 40.8 (21.5 to 84.3) <0.0001
Hospital LOS
(days, IQR)
9.7 (5.4 to 18.2) 9.3 (5.3 to 17.8) 0.002
Hospital outcome: home* 68% (56,673) 69% (64,547) 0.12
ICU mortality* 8% (6,480) 7% (6,728) <0.0001
Hospital mortality* 12% (9,989) 11% (10,494) <0.0001
*percentage (number of events); ICU, intensive care unit; LOS, length of stay;



































Figure 2 Adjusted mortality over time before and after NICE-SUGAR. Odds ratios (95% confidence intervals) for hospital mortality in all
patients during four consecutive six-month periods before (periods 1 to 4) and after (periods 5 to 8) NICE-SUGAR study (P <0.0001). NICE-SUGAR,
Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation.
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nificant, it is unlikely to be an explanation for reduced
mortality.
Implications of study findings
The glycaemic control before NICE-SUGAR in ANZ rep-
resented clinical practice at that time. It closely followed
the glycaemic control achieved in the control arm of
NICE-SUGAR enforcing the generalizability of NICE-
SUGAR study results to ANZ and justifying the choice of































Quartiles of ICUs accordi
Figure 3 Adjusted mortality in quartiles of ICUs according to change
quartiles of ICUs according to changes in mean first day glucose values (Q1
highest increase). P <0.001 for Q1, P ns (>0.01) for Q2 to 4.Glycaemic control before NICE-SUGAR was not in
the range of IIT in any of the ANZ ICUs included in our
study. This is strong evidence that before the NICE-
SUGAR study, ICUs in ANZ were not practicing glucose
control according to recommendations at the time or
failed to achieve targeted glucose control in their pa-
tients. The ICUs participating NICE-SUGAR loosened
their glucose control practice after the publication of the
study results to greater degree than the ICUs not partici-
pating in the trial. Overall, the translation of study re-
sults into practice seemed to be more prominent in
academic ICUs as well as ICUs participating in the trial.Q3 Q4
ng to change in mean 1st day glucose 
in Glu1. Odds ratios (95% confidence intervals) for mortality in
denotes ICUs with the smallest change, Q4 denotes ICUs with the
Figure 4 Interrupted time series analysis of mortality before and after NICE-SUGAR. Interrupted time series analysis of mortality before and
after NICE-SUGAR study. There was no significant vertical shift between pre and post periods (P = 0.29). NICE-SUGAR, Normoglycemia in Intensive
Care Evaluation and Surviving Using Glucose Algorithm Regulation.
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could facilitate translation of research into practice.
The extent of change in glycaemic control was clinic-
ally insignificant. It was, however, reflected by the lower
incidence of moderate hypoglycaemia. As hypoglycaemia
have been strongly associated with increased mortality,
this change appears desirable.
Patients with IDDM were outliers in glycaemic control
and hypoglycaemia rate. In addition, IDDM patients were
the only subgroup in whom the mortality did not decrease
over the study period. The recommendations for gly-
caemic control in critically ill patients do not separately
address glycaemic control in IDDM patients. As this sub-
group of patients seems to be highly different from the
overall critically ill patient population as well as other pa-
tient subgroups, a different approach to their glycaemic
control may be needed. If further studies on glycaemic
control in critically ill patients are to be conducted, appro-
priate identification and stratified randomisation for this
patient subgroup would be needed.
The observational period of our study was nearly five
years leading to a large sample size of more than 170,000
patients. Accordingly, even for small changes in the nu-
merical values between the study periods, statistical sig-
nificance was easily achieved. In order to increase the
robustness of our findings, a reduced P-value of 0.01 was
chosen to indicate statistical significance. However, even
with this conservative statistical approach, the clinicalimportance of some of the statistically significant changes
seen remains unclear.
Strengths and weaknesses
Our study has several strengths. The data in the APD
are prospectively collected for routine quality control
purposes and, therefore, they are unlikely to be biased.
We ensured the representativeness of the glycaemic con-
trol for each ICU by selecting only the ICUs that pro-
vided >80% of the first day glucose values for their
patients. Some limitations should be noted, however.
The completeness of first day glucose values for ICUs
was low in the data collected 12 years ago. Thus, we
could not analyse the effect of the first Leuven trial on
clinical practice. It can be postulated that the greatest
changes in clinical practice would have been before and
after the publication of the first pivotal RCT with tight
glucose control. However, by the time NICE-SUGAR
was conducted, such changes (if they had occurred) had
clearly dissipated. Secondly, we did not have glucose
measurements beyond the first 24 hours of the ICU stay
in the database. The first day mean glucose values, how-
ever, have been shown to have high accuracy in predicting
the glucose control of the whole ICU stay [19]. Third, our
assessment of hypoglycaemia using Day 1 data is not vali-
dated. However, although the absolute overall incidence of
hypoglycaemia may be inaccurate, the change from one
period to another using the same assessment methodology
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ANZ.Conclusions
The treatment of the control arm in NICE-SUGAR was
an almost exact replica of the standard of care at the
time of planning and execution of the study. The
changes in overall glucose control before and after
NICE-SUGAR were minor and toward looser glucose
control. These changes were greater in trial ICUs. The
incidence of moderate hypoglycaemia, but not severe
hypoglycaemia, on Day 1 decreased with such loosening
of glucose control. The results of intensive care treat-
ment continued to improve over time, as measured by
hospital mortality. These findings support the notion
that, at this stage, the glucose target prescribed in the
control arm of NICE represents an acceptable standard
of glycaemic control.Key messages
 Despite recommendations current at the time, intensive
insulin therapy was not adopted in ANZ intensive care
units before the publication of NICE-SUGAR study.
 Glucose control before NICE-SUGAR was in the
glycaemic band of the control group of NICE-SUGAR
confirming that the trial reflected current ANZ
practice at the time.
 The changes in clinical practice were small after the
result of publication of NICE-SUGAR study and
toward looser glycaemic control.
 The change to looser glycaemic control was
associated with a decrease in the incidence of
moderate hypoglycaemia but not severe
hypoglycaemia.
 Irrespective of glycaemic management, hospital
mortality and hospital length of stay continued to
decrease over the whole study period.Additional file
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patients before and after NICE-SUGAR study publication.Abbreviations
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